Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACOR NASDAQ:GNCA NASDAQ:MBOT NASDAQ:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$9.68$0.61▼$24.20$820K1.4119,299 shs416,900 shsGNCAGenocea Biosciences$0.00$0.00▼$0.00$6K1.6183,499 shsN/AMBOTMicrobot Medical$3.44+0.4%$3.15$0.85▼$4.67$156.46M1.213.49 million shs2.22 million shsVXRTVaxart$0.38+4.1%$0.38$0.26▼$0.98$87.39M1.332.76 million shs151,527 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%0.00%0.00%0.00%GNCAGenocea Biosciences0.00%0.00%0.00%0.00%+150.00%MBOTMicrobot Medical-15.56%-24.00%+10.68%+41.32%+245.45%VXRTVaxart-6.00%-4.78%+0.16%-38.46%-62.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACORAcorda Therapeutics$9.68$0.61▼$24.20$820K1.4119,299 shs416,900 shsGNCAGenocea Biosciences$0.00$0.00▼$0.00$6K1.6183,499 shsN/AMBOTMicrobot Medical$3.44+0.4%$3.15$0.85▼$4.67$156.46M1.213.49 million shs2.22 million shsVXRTVaxart$0.38+4.1%$0.38$0.26▼$0.98$87.39M1.332.76 million shs151,527 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACORAcorda Therapeutics0.00%0.00%0.00%0.00%0.00%GNCAGenocea Biosciences0.00%0.00%0.00%0.00%+150.00%MBOTMicrobot Medical-15.56%-24.00%+10.68%+41.32%+245.45%VXRTVaxart-6.00%-4.78%+0.16%-38.46%-62.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACORAcorda Therapeutics 0.00N/AN/AN/AGNCAGenocea Biosciences 0.00N/AN/AN/AMBOTMicrobot Medical 2.50Moderate Buy$12.00249.34% UpsideVXRTVaxart 3.00Buy$2.00423.97% UpsideCurrent Analyst Ratings BreakdownLatest MBOT, ACOR, VXRT, and GNCA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025MBOTMicrobot MedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $12.008/21/2025MBOTMicrobot MedicalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACORAcorda Therapeutics$117.63M0.00N/A0.02($127.17) per share0.00GNCAGenocea Biosciences$1.91M0.00N/AN/A$0.47 per share0.00MBOTMicrobot MedicalN/AN/AN/AN/A$0.17 per shareN/AVXRTVaxart$47.40M1.84N/AN/A$0.26 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACORAcorda Therapeutics-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%N/AGNCAGenocea Biosciences-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/AMBOTMicrobot Medical-$11.44M-$0.58N/AN/AN/AN/A-76.27%-67.54%11/12/2025 (Estimated)VXRTVaxart-$66.95M-$0.25N/AN/AN/A-122.63%-91.89%-38.40%11/12/2025 (Estimated)Latest MBOT, ACOR, VXRT, and GNCA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MBOTMicrobot Medical-$0.08-$0.10-$0.02-$0.10$1.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACORAcorda TherapeuticsN/AN/AN/AN/AN/AGNCAGenocea BiosciencesN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACORAcorda Therapeutics3.070.330.26GNCAGenocea Biosciences0.241.351.35MBOTMicrobot MedicalN/A12.0612.06VXRTVaxartN/A0.640.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACORAcorda Therapeutics12.71%GNCAGenocea Biosciences0.64%MBOTMicrobot Medical16.30%VXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipACORAcorda Therapeutics2.60%GNCAGenocea Biosciences1.61%MBOTMicrobot Medical4.74%VXRTVaxart2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACORAcorda Therapeutics1111.24 million1.21 millionNo DataGNCAGenocea Biosciences7058.73 million57.79 millionNot OptionableMBOTMicrobot Medical2045.55 million43.39 millionOptionableVXRTVaxart120228.94 million222.37 millionOptionableMBOT, ACOR, VXRT, and GNCA HeadlinesRecent News About These CompaniesVaxart (NASDAQ:VXRT) Shares Pass Below 200 Day Moving Average - Should You Sell?September 14 at 4:26 AM | marketbeat.comConcerned Vaxart Stockholders Condemn Board’s Decision to Adjourn Reverse Stock Split Vote at Special MeetingSeptember 10, 2025 | markets.businessinsider.comVaxart Reports Promising Phase 1 Results for Second-Generation Norovirus Vaccine Inducing Increased Fecal IgA ResponseSeptember 10, 2025 | quiverquant.comQVaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine CandidateSeptember 10, 2025 | globenewswire.comConcerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special MeetingSeptember 10, 2025 | globenewswire.comVaxart Announces Adjournment of Special Meeting of StockholdersSeptember 8, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - What's Next?September 6, 2025 | marketbeat.comVaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025September 3, 2025 | markets.businessinsider.comVaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of DirectorsSeptember 3, 2025 | markets.businessinsider.comVaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.September 2, 2025 | globenewswire.comConcerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board AccountabilitySeptember 2, 2025 | globenewswire.comVaxart Granted Extension by Nasdaq to Regain ComplianceAugust 29, 2025 | markets.businessinsider.comVaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average - Here's WhyAugust 29, 2025 | marketbeat.comVaxart Discusses Reverse Stock Split ProposalAugust 21, 2025 | tipranks.comConcerned Vaxart Stockholders Unite to Oppose Vaxart’s Latest Reverse Stock Split and Defend Stockholder RightsAugust 21, 2025 | markets.businessinsider.comConcerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder RightsAugust 21, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average - Should You Sell?August 16, 2025 | marketbeat.comVaxart, Inc. (VXRT) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | seekingalpha.comVAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue EstimatesAugust 13, 2025 | zacks.comUS orders Vaxart to stop COVID-19 trial amid mRNA wind downAugust 13, 2025 | reuters.comVaxart, Inc. Stock (VXRT) Opinions on Reverse Stock Split ProposalJuly 31, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025The Case for Buying NVIDIA Stock Ahead of the Robotics SurgeBy Thomas Hughes | August 20, 2025MBOT, ACOR, VXRT, and GNCA Company DescriptionsAcorda Therapeutics NASDAQ:ACORAcorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.Genocea Biosciences NASDAQ:GNCAGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.Microbot Medical NASDAQ:MBOT$3.44 +0.02 (+0.44%) As of 01:32 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Vaxart NASDAQ:VXRT$0.38 +0.02 (+4.12%) As of 01:08 PM EasternVaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Reddit Hits Record Highs: Why Wall Street Is Taking Notice Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
